There were also increased transcripts of immune checkpoint molecules PD-1 and PD-L1 as well as H2-K2 (major histocompatibility complex class I; Fig. 6b), consistent with an immune responsive tumor microenvironment created by the combination drug treatment. Here, CD274 is linked to neoplasm.